|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01515 CR MEDICAL
Nominal 
2.800 +0.100 (+3.704%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 9,175,645 | -6.892% | 9,854,790 | 10,107,500 | 7,901,287 | 4,447,477 |
| Cost of Sales | (7,734,872) | -3.854% | (8,044,964) | (8,201,663) | (6,595,452) | (3,513,922) |
| Gross Profit | 1,440,773 | -20.392% | 1,809,826 | 1,905,837 | 1,305,835 | 933,555 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | (30) | -99.907% | (32,153) | (208,926) | (510) | -- | |
| Change in FV & Impairment on Others | (22,284) | 181.328% | (7,921) | (272,228) | (136,130) | (355,289) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 78,338 | -20.552% | 98,603 | 90,780 | 88,068 | 83,554 | |
| Profit / (Loss) before Taxation | 747,665 | -10.851% | 838,670 | 492,921 | 422,941 | 270,475 | |
| Taxation | (191,567) | 14.764% | (166,923) | (165,031) | (94,660) | 155,389 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (60,154) | -43.182% | (105,872) | (70,210) | (62,426) | (7,949) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 495,944 | -12.358% | 565,875 | 257,680 | 265,855 | 417,915 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 40,965 | -34.060% | 62,125 | 57,031 | (22,202) | (59,612) |
| Depreciation & Amortisation | 584,927 | -5.489% | 618,896 | 610,863 | 486,406 | 182,879 |
| Directors' Emoluments | -- | -- | 11,776 | 10,515 | 10,618 | 13,079 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 39.000 | -13.333% | 45.000 | 20.000 | 21.000 | 33.000 |
| DPS (cts) | 13.400 | -- | 13.200 | 6.000 | 3.344 | 10.238 |
| Dividend Payout Ratio (%) | 34.359% | -- | 29.333% | 30.000% | 15.923% | 31.024% |
| Cash flow per share ($) | -- | -- | 1.005 | 0.945 | 0.684 | 0.566 |
| NBV per share ($) | 5.053 | -- | 4.792 | 4.482 | 7.331 | 4.975 |
| Remarks: | Real time quote last updated: 25/03/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 495,944 |
| %Change | -12.358% |
| EPS / (LPS) | RMB 0.390 |
| NBV Per Share (¥) | RMB 5.053 |